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Background: Cytosolic nonspecific dipetidase (CN2) belongs to the family of M20 metallopeptidases. It was stated
in previous articles that higher expression levels of CN2 were observed in renal cell carcinoma and breast cancer.
Our study explored the correlation between CN2 and colon carcinogenesis.
Methods: We analysed the relationship between 183 patients clinicopathological characteristics and its CN2
expression. To detect the levels of CN2 in colon cancer cell lines and colon cancer tissues by western blot. To verify
cell proliferation in colon cancer cells with knockdown of CNDP2 and explore the causes of these phenomena.
Results: The expression levels of CN2 in clinical colon tumors and colon cancer cell lines were significantly higher
than that in normal colon mucosa and colon cell lines. The difference in CN2 levels was associated with tumor
location (right- and left-sided colon cancer), but there was no significant association with age, gender, tumor size,
tumor grade, tumor stage or serum carcinoembryonic antigen (CEA). Knockdown of CNDP2 inhibited cell proliferation,
blocked cell cycle progression and retarded carcinogenesis in an animal model. The signaling pathway through which
knockdown of CNDP2 inhibited cell proliferation and tumorigenesis involved in EGFR, cyclin B1 and cyclin E.
Conclusions: Knockdown of CNDP2 can inhibit the proliferation of colon cancer in vitro and retarded carcinogenesis
in vivo.
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Colorectal cancer (CRC) is the third most commonly di-
agnosed cancer in males and the second most common
in females, with over 1.2 million new cancer cases and
608,700 deaths estimated to have occurred in 2008 [1].
CRC was categorized into either proximal (right) or dis-
tal (left) location relative to the splenic flexure. This
method appears very simple, but cumulative evidence
found that underlying molecular features are different in
right- and left-sided colon cancers. Bufill et al. was the
first to comprehensively propose that colon cancer
found in the proximal and distal locations of the colon
may follow different biological pathways [2]. The reason* Correspondence: miaomy@163.com; shihp@mail.sysu.edu.cn
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reproduction in any medium, provided the orfor this difference is uncertain, but it could partly be ex-
plained by the different embryological development of
the two segments of the colon, which may result in dif-
ferent genetic mutants or other molecular biological pat-
terns of tumors, which therefore represent two separate
disease entities [3].
Cytosolic nonspecific dipeptidase (CN2), named tissue
carnosinase previously, belongs to the family of M20 metal-
lopeptidases. It degrades carnosine (β-alanyl-L-histidine),
which is an important bioactive dipeptide [4]. However,
there are contradictory arguments on the function of
CN2 in degrading carnosine. The study of Teufel et al.
showed that little activity of CN2 was detectable under
physiological conditions [4], whereas Pandya et al. sug-
gested that carnosine can be hydrolyzed by CN2 under
physiological conditions [5]. An HPLC-based method was
used in the former study to detect the activity of CN2
while an MS-based assay in the latter study. The different
methods might lead to the contradictory conclusions.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Table 1 Association between clinicopathological variables
and CNDP2 expression in 150 patients with CC
Variables n (%) CNDP2 expression P value
Low High
Age — yr Mean 57.5 56.2 ± 10.7 58.5 ± 9.5 0.894a
Gender—n (%)
Male 76 (50.7) 29 (44.6) 47 (55.3) 0.195b
Female 74 (49.3) 36 (55.4) 38 (44.7)
Tumour size —n (%)
≤ 5 cm 44 (29.3) 22 (33.3) 22 (26.2) 0.340b
> 5 cm 106 (70.7) 44 (66.7) 62 (73.8)
Lymph nodes
metastasis—n (%)
No 76 (50.7) 38 (57.6) 38 (45.2) 0.134b
Yes 74 (49.3) 28 (42.4) 46 (54.8)
Tumour grade—n (%)
1 20 (21.5) 8 (32.4) 12 (7.1) 0.434b
2 106 (53.9) 50 (46.0) 56 (64.3)
3 24 (24.6) 8 (21.6) 16 (28.6)
Tumor stage—n (%)
I 24 (16.0) 12 (18.2) 12 (14.2) 0.927b
II 46 (30.7) 20 (30.3) 26 (31.0)
III 62 (41.3) 26 (39.4) 36 (42.9)
IV 18 (12.0) 8 (12.1) 10 (11.9)
CEA—n (%)
Negative 96 (64.0) 44 (63.8) 52 (64.2) 0.956b
Positive 54 (36.0) 25 (36.2) 29 (35.8)
Tumor location—n (%)
RCC 84 (56.0) 28 (42.4) 56 (66.7) 0.003b*
LCC 66 (44.0) 38 (57.6) 28 (33.3)
RCC—n (%)
Male 42 (50.0) 9 (33.3) 33 (57.9) 0.035b*
Female 42 (50.0) 18 (66.7) 24 (42.1)
LCC—n (%)
Male 34 (51.5) 20 (52.6) 14 (50.0) 0.833b




Xue et al. BMC Gastroenterology 2014, 14:96 Page 2 of 8
http://www.biomedcentral.com/1471-230X/14/96Many researches showed that carnosine can inhibited the
growth of malignant cells. Carnosine was recently re-
ported that it retarded tumor growth in vivo mouse
models and inhibited the proliferation of colon cancer cell
in vitro [6,7]. The activity of CN2 can strongly be inhibited
by bestatin [4]. A randomized phase III study of bestatin
as a postoperative adjuvant treatment in patients with
stage I squamous cell lung cancer was performed, and
statistically significant clinical improvement in overall
survival and disease-free survival was ascertained [8].
However, the mechanisms of the antitumor effects of
bestatin and carnosine are not fully understood. Current
studies about the relationship between CN2 and cancer
have not come to an accordant conclusion. The expres-
sion levels of CN2 were high in breast cancer and kidney
cancer but low in pancreatic cancer and hepatocellular
carcinoma [9-13]. Thus, the research on the correlation
between CN2 and colon cancer could reveal the mechan-
ism driving colon cancer growth.
In this study, we examined CN2 expression in colon mu-
cosa (CM), benign colon diseases (BCD) and colon cancers
(CC). We also examined the effect of CN2 in tumor cell
growth, colony formation and colon cancer cell tumorigen-
icity in nude mice.
Methods
Patients and specimens
One hundred fifty colon cancer samples and corre-
sponding normal colon samples (at least 5 cm away from
the tumor margin) and thirty three colon polyp were ob-
tained and pathologically confirmed at the first affiliated
hospital of Sun Yat-Sen University. 150 samples came
from the patients with colon adenocarcinom who under-
went curative resection between 2007 and 2009, and the
other 33 ones were obtained from the patients with
benigh colon diseases (BDC) by colonoscopy. The clin-
ical characteristics of all these patients are summarized
in Table 1. Clinical stages were classified according to
the TNM stages of colorectal cancer defined by the
Union for International Cancer Control (UICC). Eight
tumor tissues and corresponding normal colon mucosa
tissues were used for western blotting analysis. All sam-
ples were anonymously coded in accordance with local
ethical guidelines, and written informed consent was ob-
tained. This study was approved by the Review Board of
Sun Yat-Sen University.
Immunohistochemistry
Paraffin sections (4 mm thick) were deparaffinized and
rehydrated followed by immersing in 3% H2O2 to
quench endogenous peroxidase activity. Then, the sec-
tions were treated with 0.01 M citrate buffer (pH 6.0)
and blocked with 5% normal goat serum, followed by
incubation with a monoclonal anti-CNDP2 antibody(1:400; Proteintech, Chicago, IL) overnight at 4°C. These
primary antibodies were diluted in PBS buffer containing
5% normal goat serum. The negative control for each slide
was incubated with 5% normal goat serum without pri-
mary antibody. The sections were then incubated with
HRP-conjugated anti-rabbit IgG for 60 min at room
temperature and imaged with a ChemMate TM Envision
TM Dectection Kit (DAKO). Scoring was performed by
two pathologists.
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The following human colon normal and cancer cell lines
were used: FHC was purchased from the American Type
Culture Collection; DLD-1, LS174T, LoVo, RKO HCT116,
HT29 and SW480 were provided by the Institute of
Biochemistry and Cell Biology of the Chinese Academy of
Science. All cells were maintained in RPMI 1640 (Biowest)
medium supplemented with 10% FBS (Biowest), 100 U/ml
penicillin, 100 μg/ml streptomycin sulphate, and 1 mM
sodium pyruvate at 37°C in 5% CO2. The cells were trypsi-
nized with trypsin-EDTA.
Knockdown of CNDP2 by RNA interference (RNAi)
Three RNAi candidate target sequences to human CNDP2
(Additional file 1: Table S1) were synthesized according to
the structure of a GV112 (hU6-MCS-CMV-Puromycin)
viral vector (Genechemgene, Shanghai, China) and then
inserted into a linearized vector. RKO cells were subcul-
tured at 1 × 105 cells per well in 6-well tissue culture
plates. After 24 h culture, cells were infected by recombin-
ant lentivirus vectors at a multiplicity of infection (MOI)
of 10 with Enhanced infection solution and cultured in
RPMI-1640 medium containing 10% FBS. These cells
were then selected with puromycin (Sigma-Aldrich, Cat.
P9620) for 48 h. Puromycin-resistant clones were gener-
ated and screened using western blot analysis.
Western blot analysis
Proteins from cells or fresh tissues were extracted in
RIPA lysis buffer containing a protease inhibitor cocktail
(Roche). The supernatant was collected, and the protein
concentration was quantified using a protein assay re-
agent (BCA, Beyotime, Shanghai). The proteins were
separated by SDS-PAGE, transferred to a nitrocellulose
membrane and incubated with the monoclonal antibody
anti-CNDP2 (Proteintech, Chicago, IL), Cyclin E, Cyclin
B1, EGFR, phospho-ERK1/2, ERK1/2, phospho-AKT, AKT,
phospho-mTOR and mTOR (Cell Signaling Technology,
Beverly, USA) at 4°C overnight. Thereafter, membranes
were incubated with HRP-conjugated anti-rabbit IgG
(1:5000) for 60 min at room temperature. The reactions
were visualized using enhanced chemiluminescence and
detected on photographic film.
Cell growth assay
The cells were seeded in a 24-well plate at a density of 8000
cells/well and then cultured for 6 d. Cells were trypsinized
and counted every 24 h.
Colony formation
The cells (3 × 102) were plated onto a 6-well plate. Plated
cells were incubated at 37°C for 10 d. The plates were
then stained with crystal violet, and colonies containing
more than 50 cells were counted.Flow cytometry
Ethanol-fixed cells were incubated with RNase A (100 mg/
ml) for 30 min at 37°C and propidium iodide (PI, 50 mg/ml)
for 30 min at 4°C. PI fluorescence was measured in a
FACScalibur flow cytometer (BD). Data were collected from
10,000 single-cell events, and cell cycle phase distributions
were calculated using MODFIT software (Verity Software
House).
Tumorigenicity assay in nude mice
The tumor formation ability of CNDP2-transfected RKO
cells was evaluated by injecting cell suspensions into
BALB/c nude male mice. For each mouse, 1 × 106 cells
of RKO cell (shRNA_CNDP2 or vector-transfected) were
injected into buttocks. After 4 to 5 weeks, mice were
sacrificed, and each tumor was dissected for weighing.
Each experimental group consisted of five mice, and the
experiment was repeated twice. All animal experiments
were performed with institutional approval and con-
formed to the Cancer Research guidelines for the welfare
of animals in experimental neoplasia at Sun Yat-Sen
University.
Statistical analysis
Baseline characteristics of patients and the levels of CN2
in colon tissue were compared using Student’s T-test
(continuous variables) and Chi-squared (χ2) tests (cat-
egorical variables). All statistical tests and corresponding
P-values reported were for two-sided tests, and statistical
analysis was performed using SPSS software version 12.0.
P-values < 0.05 were considered statistically significant.
Results
CN2 expression in colon cancers and cells
To explore the function of CN2 in colon cancer, we in-
vestigated CN2 expression in colon cancer tissues and
peritumoral tissues. One hundred eighty-three samples
from patients with colon disease, including 33 BCD sam-
ples, 150 CC samples and 150 CM samples were examined
by immunohistochemistry. The CM samples consisted of
peritumoral tissues that were resected at least 5 cm away
from the tumor margin. The peritumoral epithelium and
BCD displayed very weak staining and CC displayed very
strong staining (Figure 1A) in the stained samples, and
these samples displayed mainly CN2 expression in the
cytoplasm (Figure 1A). 89.7% (126 out of 150) of the CM
showed weak staining, while 75.8% (25 out of 33) of BCD
expressed CN2 at low levels; 24.2% (8 out of 33) had higher
levels. Notably, 50.7% (76 out of 150) of the CC samples
displayed very strong cytoplasmic staining (Table 2 and
Figure 1A). CN2 expression was significantly higher in CC
than in BCD (p < 0.006) or CM tissues (p < 0.0001). In
BCD tissues, CN2 expression was slightly higher than in
CM; however, there was no statistical differences between
Figure 1 CN2 expression in clinical colon tumors and cell lines. (A) CN2 expression in CM, BCD and CC tissues.. Scale bars = 20 μm. (B)
Western blot of CN2 in colon cancer cells and normal cells. (C) Western blot of CN2 in CC tissues and peritumoral tissues.
Table 2 Association between CNDP2 expression and
groups of colon disease
Groups CNDP2 expression P value
n (%) Low High
CM 150 (100) 126 (89.7) 24 (10.3) <0.0001a*
BCD 33 (100) 25 (75.8) 8 (24.2)
CC 150 (100) 74 (49.3) 76 (50.7)
CM vs.BCD 0.259b
BCD vs. CC 0.006b*
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or negative staining (Figure 1A). Thus, CN2 immunostain-
ing in CC was stronger than in their peritumoral counter-
parts and BCD. CN2 expression is markedly up-regulated
in colon cancer. To further confirm our hypothesis, we
examined CN2 expression in colon epithelial cells. Eight
types of colon cells, including seven colon cancer cell lines
(RKO, HCT116, DLD-1, LS174T, HT29, SW480 and
LoVo) and the normal colon epithelial cell line (FHC),
were collected. CN2 expression was extremely low in FHC
cells, while all seven colon cancer cell lines displayed high
CN2 expression (Figure 1B). CN2 expression in CC tissues
and their peritumoral counterparts was also compared
by western blotting. CN2 expression was significantly
higher in tumors than in their peritumoral counter-
parts (Figure 1C).
Association of CN2 expression with clinicopathological
parameters
The clinical characteristics of 150 patients with CC and
the correlation of baseline characteristics with CN2 ex-
pression were reviewed. CN2 expression was signifi-
cantly associated with tumor location, but there was no
significant association with age, gender, tumor size,
tumor grade, tumor stage or serum CEA by statistical
analysis (Table 1). There were 84 right-sided colon can-
cers (RCC) and 66 left-sided colon cancers (LCC) in all
150 patients. CN2 expression in RCC was significantlyhigher than in LCC (p = 0.003, Table 1). CN2 expression
in male RCC was stronger than in female RCC (p = 0.035,
Table 1), but there was no statistical difference between
male LCC and female LCC (p = 0.833, Table 1).
CN2 is associated with cell proliferation, cell cycle
progression and tumorigenicity
In order to analyze the effects of CN2 on proliferation,
we knocked down endogenous CNDP2 in RKO with
shRNA_CNDP2. Knockdown of CNDP2 significantly
inhibited the proliferation of RKO (p < 0.01, Figure 2A).
After knockdown of CNDP2, the colony number was de-
creased (p < 0.01, Figure 2B). Moreover, RKO transfected
Figure 2 Association of CN2 expression with colon cancer cell proliferation and colony formation. (A). RKO cells transfected with
shRNA_CNDP2 showed a reduced growth rate. (B) RKO cells transfected with shRNA_CNDP2 showed reduced colony formation as
compared to the controls. *p < 0.05.
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tion in the G2/M phase (p < 0.05, Figure 3A) and a reduc-
tion in the proportion in S phase (p < 0.05, Figure 3A).
Knockdown of CNDP2 reduced the S-phase fraction
(SPF) and the number of cells arrested in G2/M. However,
knockdown of CNDP2 did not affect apoptosis (Figure 4).
Thus, knockdown of CNDP2 inhibited the proliferation
of colon cancer cells. Additionally, knockdown of CNDP2
resulted in the decrease of cyclin E, cyclin B1 and EGFR
expression in RKO cells (p < 0.05, Figure 3B), while there
were no statistical differences in phospho-ERK1/2, ERK1/
2, phospho-AKT, AKT, phospho-mTOR and mTOR ex-
pression (Figure 5). Furthermore, knockdown of CNDP2
retarded RKO tumorigenicity in nude mice (p < 0.05,
Figure 3C).
Discussion
CN2 expression exists in different human tissues ubiqui-
tously [4]. The pathophysiological relevance of CN2 is
degradation of carnosine (β-alanyl-L-histidine), which is
an important bioactive dipeptide. However, there are
contradictory arguments about the function of CN2.
Teufel et al. stated that CN2 showed little bioactivity at
pH7.5 and degraded carnosine at pH9.5, whereas Pandya
et al. suggested that CN2 could degrade carnosine under
physiological conditions and there was no significant
change in the activity of CN2 with the change of pH [5].
An HPLC-based method was used in the former study
to detect the activity of CN2 while an MS-based assay inthe latter study. The different methods might lead to the
contradictory conclusions. Biochemically, carnosine has
the properties of pH-buffering, metal-ion chelation, anti-
oxidant, and the capacity to defend against formation of
advance dglycation and lipoxidation end-products. These
properties determine its physiological roles [14].
In our study, we found that CN2 expression is dramat-
ically increased in clinical colon cancer samples and
colon cancer cells. In clinical samples, CN2 expression
was significantly higher in CC than in BCD and CM tis-
sues. In colon cell lines, CN2 expression was statistically
higher in RKO cells as compared to normal FHC colon
cells. These results suggest that high CN2 expression is as-
sociated with tumorigenesis. Furthermore, we found that
CN2 expression in RCC is remarkably higher in compari-
son to LCC.
CC was divided into RCC and LCC relative to the splenic
flexure. RCC consists of the cecum, ascending colon, hep-
atic flexure, and transverse colon. LCC consists of the
splenic flexure, descending colon and sigmoid colon. There
were many differences in pathological characteristics, clin-
ical symptoms and biological features. Cancers on the right
side tend to be exophytic and present with symptoms
such as anemia, and left-sided cancer tends to be cir-
cumferential and can obstruct the bowel. Several groups
have continued to develop the theme of differences be-
tween right- and left-sided colon cancers, and they have
suggested that there are differences in epidemiology,
clinical manifestation, pathology and prognosis between
Figure 3 Association of CN2 expression with colon cancer cell cycle progression and tumorigenicity. (A) Cell-cycle phase distributions
were analyzed by a FACScalibur flow cytometer. These experiments were repeated 3 times, and the symbols represent the mean values of
triplicate tests (mean ± SD). (B) Western blotting analysis of cyclin E, cyclin B1 and EGFR expression. The experiment was independently repeated
at least 3 times. (C) Knockdown of CNDP2 inhibited tumor formation in nude mice. Nude mice were inoculated with RKO stably transfected with
empty vector and shRNA_CNDP2 expression vectors. *p < 0.05.
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RCC is more likely to be detected at an advanced stage
with severe symptoms, and survival is significantly worse
in patients with right-sided cancer [16,17]. However, the
impact of tumor location itself on status and survival re-
mains uncertain. Our results showed that CN2 expression
in RCC was significantly higher than in LCC, which could
explain why there are many different biological character-
istics in the two segments of colon cancer. Moreover, weFigure 4 Association of CN2 expression with cell apoptosis. Cell apopt
were repeated 3 times, and the symbols represent the mean values of triplalso found CN2 expression in male RCC was stronger
than in female RCC, but there was no statistical difference
between male LCC and female LCC. This result may be
due to a small sample number.
Tripathi et al. reported that CN2 expression was re-
markably higher in breast carcinomas in situ than nor-
mal breast cancer tissues and reduced mammoplasty
breast tissues [9]. Two other studies demonstrated high
expression of CN2 in kidney cancer tissues [10,11]. Ourosis was analyzed by a FACScalibur flow cytometer. These experiments
icate tests (mean ± SD).
Figure 5 Western blotting analysis of phospho-ERK1/2, ERK1/2,
phospho-AKT, AKT, phospho-mTOR and mTOR expression.
The experiment was independently repeated at least 3 times.
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dence suggest that down-regulation of CNDP2 inhibits
the proliferation of colon cancer. First, the expression
levels of CN2 was significantly associated with EGFR
expression, and EGFR serves as a marker of cell pro-
liferation, migration and metastasis. Thus, elevated CN2
expression is likely associated with the proliferation of
colon cancer cell. Second, down-regulation of CNDP2
in colon cancer cells inhibited cell proliferation and in-
fluenced cell cycle. Finally, down-regulation of CNDP2
inhibited tumor formation in nude mice. Collectively,
these data suggest a role for CN2 in cell proliferation, but
there are opposing views about CN2. Lee et al. reported
that the CNDP2 gene and its splicing variant CPGL-B
serve as growth-suppressor genes in pancreatic cancer
[12]. Zhang et al. reported that CPGL-B significantly in-
hibits cell viability, colony formation, cell invasion and
tumor formation in nude mice [13]. These contradictory
results could be explained by differences in organization
and cell type.
The signaling pathway through which CN2 promotes
cell proliferation and tumorigenesis is unknown. We
found that cyclin E expression was significantly lower
after knockdown of CNDP2, which resulted in the re-
duction of SPF. Cyclin E, the essential S-phase kinase in
Drosophila, promotes the G1/S-phase transition. Cyclin
E shows cyclic expression and accumulates only during
late G1, where it associates with CDK2 and promotes
entry into S phase [18,19]. Amplification of cyclin E and
CDK2 genes play a role in colorectal tumorigenicity
[20]. To estimate the rate of cell proliferation, the SPFwas frequently used in breast cancer, thyroid cancer and
oral leukoplakia [21-23]. In colon cancer, high SPF was
significantly associated with a poor prognosis [24,25].
We also found that knockdown of CNDP2 reduced cyc-
lin B1 expression, which increased the levels of G2. Cells
were arrested in G2/M. Cyclin B1 is one of the key regu-
lators of the G2/M transition [26], and gene amplification
or overexpression of cyclin B1 is associated with cell
growth and tumorigenesis in colon cancer [27]. EGFR ac-
tivation is required for progression from G2 to M phase
[28]. Cyclin B1 expression is induced by various growth
factors that could be activated via the EGFR/ERK pathway
[29]. We found that suppression of CNDP2 blocked cell
cycle progression and decreased the expression of cyclin
E, cyclin B1 and EGFR in colon cancer cells. These results
suggested that products of CN2 reaction may affect the
expression of EGFR, cyclin B1 and cyclin E.
There are several limitations of our study. We could
not determine the CN2 activity, which is crucial in
pathophysiological process. The content of carnosine in
the supernatant of proteins from fresh extracted tissues
(colon cancer samples and corresponding normal colon
samples) was measured by HPLC-based method and
MS-based assay, however we got the negative results. So
we don’t suggest that knockdown of CNDP2 inhibited
cell proliferation is linked to the blunted degradation of
carnosine. It is equally not clear whether there is the
content of carnosine in colon cancer and colon mucosa.
The further study will focus on the relationship between
the activity of CN2 and colon cancer. We will also study
whether CN2 expression will affect the prognosis of pa-
tients with colon cancer.
In conclusion, The strong CN2 expression that we ob-
served in neoplastic colon cells and tumor tissues sug-
gested a potential role for CN2 in colon tumorigenesis.
Knockdown of CNDP2 retarded the growth of tumor
cells and colony formation, and inhibited the tumorigen-
icity of colon cancer cell (RKO) in nude mice. Our work
demonstrated that CNDP2 promoted the growth of can-
cer cells. We found that the expression of CN2 varied by
colon location, which may provide a clue to the mechan-
ism in right- and left-sided colon tumorigenicity. Our re-
sults suggested that CN2 could be a useful target for
colon cancer therapy.
Conclusions
Our results suggested that knockdown of CNDP2 inhib-
ited cell proliferation in vitro and retarded carcinogen-
esis in vivo.Additional file
Additional file 1: Table S1. RNAi candidate target sequences for CNDP2.
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